Using animal models to determine the significance of complement activation in Alzheimer's disease by Loeffler, David A
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Journal of Neuroinflammation
Open Access Review
Using animal models to determine the significance of complement 
activation in Alzheimer's disease
David A Loeffler*
Address: Department of Neurology, William Beaumont Hospital Research Institute, Royal Oak, MI 48073, USA
Email: David A Loeffler* - DLoeffler@beaumont.edu
* Corresponding author    
Alzheimer's diseaseanimal modelscomplement activationtransgenic mice
Abstract
Complement inflammation is a major inflammatory mechanism whose function is to promote the
removal of microorganisms and the processing of immune complexes. Numerous studies have
provided evidence for an increase in this process in areas of pathology in the Alzheimer's disease
(AD) brain. Because complement activation proteins have been demonstrated in vitro to exert both
neuroprotective and neurotoxic effects, the significance of this process in the development and
progression of AD is unclear. Studies in animal models of AD, in which brain complement activation
can be experimentally altered, should be of value for clarifying this issue. However, surprisingly little
is known about complement activation in the transgenic animal models that are popular for
studying this disorder. An optimal animal model for studying the significance of complement
activation on Alzheimer's – related neuropathology should have complete complement activation
associated with senile plaques, neurofibrillary tangles (if present), and dystrophic neurites. Other
desirable features include both classical and alternative pathway activation, increased neuronal
synthesis of native complement proteins, and evidence for an increase in complement activation
prior to the development of extensive pathology. In order to determine the suitability of different
animal models for studying the role of complement activation in AD, the extent of complement
activation and its association with neuropathology in these models must be understood.
Background
Alzheimer's disease and complement activation
A variety of inflammatory processes are increased in
regions of pathology in the Alzheimer's disease (AD)
brain [1-4]. There is a reciprocal relationship between this
local inflammation and senile plaques (SPs) and neurofi-
brillary tangles (NFTs); both SPs and NFTs, as well as
damaged neurons and neurites, stimulate inflammatory
responses [5], and inflammatory processes exert multiple
effects, some of which promote neuropathology [6-8].
Numerous retrospective studies have shown that long-
term administration of nonsteroidal anti-inflammatory
drugs (NSAIDs) to individuals with arthritis significantly
reduces the risk for these individuals for developing AD
[9]. These findings, together with the demonstration of
elevated glial cell activation [10-12], complement activa-
tion [13-15], and increased acute phase reactant produc-
tion [16-19] at sites of pathology in the AD brain, support
the hypothesis that local inflammation may contribute to
the development of this disorder [20]. Although a short-
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term trial of AD patients with the NSAID indomethacin
suggested protection from cognitive decline [21], subse-
quent trials with other anti-inflammatory drugs have
found no evidence for slowing of the dementing process
[22-25]. These findings underscore the current perception
of CNS inflammation as a "double edged sword" [26,27],
with neuroprotective roles for some inflammatory com-
ponents and neurotoxic effects for others [28-30].
The significance of complement activation, a major
inflammatory mechanism, in AD is particularly problem-
atic. The complement system is composed of more than
30 plasma and membrane-associated proteins which
function as an inflammatory cascade. Complement acti-
vation promotes the removal of microorganisms and the
processing of immune complexes. The liver is the main
source of these proteins in peripheral blood, but they are
also synthesized in other organs including the brain [31].
Protein fragments generated during activation of the sys-
tem enzymatically cleave the next protein in the sequence,
generating a variety of "activation proteins" with diverse
activities (Table 1). Three complement pathways, the clas-
sical, alternative, and lectin-mediated cascades, have been
identified (Fig. 1). Full activation results in the generation
of C5b-9, the "membrane attack complex" (MAC), which
penetrates the surface membrane of susceptible cells on
which it is deposited and may result in cell death if present
in sufficient concentration. The presence of early comple-
ment activation proteins [32-37] and of the MAC [38-42]
has been demonstrated by immunocytochemical staining
in the AD brain. Subsequent studies found that comple-
ment activation increases Aβ aggregation [43,44] and
potentiates its neurotoxicity [45], attracts microglia
[46,47], promotes microglial and macrophage secretion
of inflammatory cytokines [48,49], and induces neuronal
injury, and sometimes neuronal death, via the MAC [50].
These findings suggested that complement activation
might contribute to the neurodegenerative process in AD.
However, recent studies have also revealed neuroprotec-
tive functions for some complement activation proteins,
including in vitro protection against excitotoxicity [51,52]
and Aβ-induced neurotoxicity [53], as well as anti-apop-
totic effects [54,55]. Further, C1q, the first complement
protein to be deposited on cell membranes during activa-
tion of the classical complement sequence, may facilitate
the clearance of Aβ by microglia [56], although this is con-
troversial [57]. Understanding the role of complement
activation in AD is of clinical relevance because some
complement-inhibiting drugs are available, and others are
being developed (see reviews by Sahu and Lambris [58],
and Morgan and Harris [59]). Conditions for which these
agents are currently being investigated include stroke [60],
organ transplantation [61], glomerulonephritis [62],
ischemic cardiomyopathy [63], and hereditary
angioedema [64]. Modulation of CNS complement acti-
vation in experimental animal models of AD, both by
treatment with complement-inhibiting drugs and by gen-
eration of AD-type pathology in complement-deficient
animals, should be useful for obtaining a greater under-
standing of the role of this process in the development of
AD-type pathology. Unfortunately, knowledge of the
extent of complement activation in animal models is lack-
ing. This paper will review (a) criteria for an optimal ani-
mal model to study this issue, (b) present knowledge
about complement activation in animal models of AD,
and (c) additional animal models which offer alternatives
for addressing this question.
Criteria for an optimal animal model for studying AD-
related complement activation
While animal models of human disease generally have
similar pathological findings to the human disorders, dis-
tinct differences remain. These models may be appropri-
ate for studying some aspects of a disease process, while
less suitable for others. To determine the significance of
complement activation in the development of AD-type
pathology, for example, some animal models may be of
value primarily for investigating the relationship between
early complement activation and SP and NFT formation,
whereas others may be more relevant for studying the role
of the MAC in neuronal loss.
Table 1: Biological activities of complement activation proteins, with relevance to AD.
Name Biological activity
C1q Enhances Aβ aggregation [43,44]; may facilitate Aβ clearance [56]; enhances Aβ-induced cytokine secretion by microglia [49]
C3a Anaphylatoxin (increases capillary permeability) [155] ; protects neurons vs. excitotoxicity [52]
C3b Immune adherence and opsonization [89] (may facilitate Aβ clearance by phagocytic microglia)
C4a Anaphylatoxin (weak) [156]
C5a Anaphylatoxin; protects neurons vs. excitotoxicity [51]; chemotaxic attraction of microglia [46,47]; inhibits apoptosis 54; increases 
cytokine release from Aβ-primed monocytes [48]
C5b-9 Neurotoxicity [50]; sublytic concentrations may have both pro- and anti- inflammatory activities [157]Journal of Neuroinflammation 2004, 1:18 http://www.jneuroinflammation.com/content/1/1/18
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1. Complete activation of complement
Investigators at the Academic Hospital Free University in
Amsterdam first reported the presence of early activation
proteins in the classical complement cascade in the AD
brain [32-34,36,37]. The MAC was not detected. How-
ever, further studies by other laboratories convincingly
demonstrated the MAC, by a variety of techniques, in AD
specimens [38-42]. The Dutch group has more recently
reported detection of the MAC in brain specimens from
subjects with dementia with Lewy bodies who met
CERAD neuropathological criteria for AD [65]. The MAC
has similarly been reported in SPs from subjects with
Down's syndrome [66] and with familial British dementia
[67], disorders in which typical AD-type neuropathology
is present. An optimal animal model for studying AD-
related complement activation should therefore have
complete complement activation.
Schematic diagram of classical, alternative, and lectin complement activation pathways Figure 1
Schematic diagram of classical, alternative, and lectin complement activation pathways. There is evidence for activation of the 
classical and alternative pathways in the AD brain. (Adapted from Sahu and Lambris, 2000 [58]).
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2. Association of complement activation proteins with 
neuropathology
Complement proteins are detectable on or closely associ-
ated with SPs, NFTs, and dystrophic neurites in the AD
brain. These findings are in agreement with in vitro studies
indicating that Aβ and tau protein, the major components
in SPs and NFTs, can fully activate human complement
[42,68-71]. Although the above studies suggested that
complement is activated principally by the aggregated
forms of Aβ and tau, soluble, non-fibrillar Aβ may also be
capable of activating complement [72]. In contrast to the
robust staining of complement proteins in mature
plaques, immunoreactivity to these proteins in diffuse
plaques has generally been below the level of detection,
though it has been reported in some studies [36,73,74].
Complement activation in the AD brain is increased pri-
marily in regions containing extensive pathology (e.g., the
hippocampus and cortex), and whether early complement
components are also present in the diffuse plaques that
develop in the AD cerebellum is controversial [74,75].
The above findings suggest that complement activation in
an optimal animal model of AD should be associated with
SPs and, in those models in which neurofibrillary pathol-
ogy occurs, with NFTs.
3. Initiation of complement activation early in development of 
pathology
How the increased complement activation in AD relates
to the development of SPs and NFTs, and to neuronal loss,
is unclear. Immunocytochemical staining for
complement activation proteins in the aged normal
human brain is generally faint, and may be below the
level of detection [42,69,73]; of relevance is a recent
report describing extensive neuron-associated C1q reac-
tivity in a cognitively normal subject with neuropatholog-
ical findings limited to diffuse cortical plaques [76].
Elderly "high pathology controls," lacking dementia but
with increased numbers of entorhinal NFTs and neocorti-
cal Aβ deposits, have a slight increase in the percentage of
C5b-9-immunoreactive plaques in comparison with aged
normal subjects, though this percentage is far lower than
in the AD brain [39]. A recent study in our laboratory [77]
used enzyme-linked immunosorbent assay (ELISA) to
measure the concentrations of two early complement acti-
vation proteins, C4d and iC3b, in brain specimens from
AD and normal subjects. ELISA is more sensitive than
immunocytochemical staining, though it provides no
information regarding the cellular association of comple-
ment immunoreactivity. Increased concentrations of
these early complement activation proteins were present
in some aged normal specimens. These reports suggest
that early complement activation may increase prior to
the development of plaques and NFTs. Similar findings
are desirable in an optimal animal model for studying
AD-related complement activation.
4. Increased CNS production of native complement proteins
Both mRNA expression and protein synthesis of native
complement proteins are increased in the AD brain [78-
80]. (Note: the distinction between detection of native
complement proteins, vs. detection of complement acti-
vation proteins, has frequently been blurred. In some
studies in which immunoreactivity to complement activa-
tion proteins (C3c, C4c, C4d) has been reported, the
antisera used were also capable of detecting the respective
native complement proteins (C3 or C4) [40,80]. Only
when antisera are used whose immunoreactivity is limited
to activation-specific neo-epitopes can complement acti-
vation be confirmed. The paucity of antisera which can
detect complement activation proteins in experimental
animal models is a significant obstacle to determining the
extent of complement activation in these models.) In
addition to neurons, complement proteins are synthe-
sized by other cells in the CNS including microglia, astro-
cytes, oligodendrocytes, and endothelial cells [31]. The
biological effects of these activation proteins are mediated
by numerous regulatory proteins including CD59, clus-
terin, vitronectin, C1-inhibitor, C4-binding protein,
decay-activating factor, and Factor H, which inhibit differ-
ent steps in the complement cascade. All of these regula-
tory proteins are produced in the human brain, but less is
known about their CNS synthesis in other species [31].
The status of some of these regulatory proteins in AD is
unclear; for example, there are conflicting reports regard-
ing the up-regulation of C1-inhibitor [81,82] and CD59
[41,82,83]. Thus, while an optimal animal model for
studying AD-related complement activation should have
up-regulated CNS synthesis of complement proteins, the
alterations that should be present in complement regula-
tory proteins are less clear.
5. Alternative as well as classical complement activation
Complement activation in the AD brain was initially
thought to be limited to the classical pathway, but recent
reports have also indicated increased concentrations of
the alternative activation factors Bb and Ba, and Factor H,
a regulatory factor for the alternative pathway, in the AD
brain [84,85]. Alternative complement activation has also
been reported in other familial dementias with patholo-
gies similar to AD [67]. Therefore, while activation of the
classical pathway is an absolute requirement for an opti-
mal animal model of AD-related complement activation,
an increase in the alternative pathway is also desirable.
Complement activation in animal models of AD: present 
knowledge
The examination of complement activation in experimen-
tal models of AD has been limited to mice and rats. The
extent of complement activation and its relationship to
the development of AD-type neuropathology have gener-
ally not been determined in these studies.Journal of Neuroinflammation 2004, 1:18 http://www.jneuroinflammation.com/content/1/1/18
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APP/sCrry mouse
Increased complement activation was induced by over-
production of transforming growth factor beta1 (TGF-β1)
in transgenic mice expressing mutations in the human
amyloid precursor protein (hAPP) gene. The APP muta-
tions expressed in these mice have been associated with
early-onset, familial AD [86]. The TGF-β1 overproduction
resulted in a 50% reduction in Aβ accumulation in the
hippocampus and cerebral cortex [87]. Because the pro-
duction of soluble Aβ was unchanged, these results sug-
gested that reduction in Aβ may have been due to its
increased clearance by microglia. A subsequent study by
the same investigators [88] found that the mRNA level of
C3 in the cerebral cortex was 5-fold higher in APP/TGF-β1
mice than in APP mice at 2 months of age (prior to depo-
sition of Aβ) and 2-fold higher at 12–15 months, when
senile plaques are present. Thus, in this model, increased
CNS synthesis of C3 precedes senile plaque formation.
Because C3b, an activation protein produced by cleavage
of C3, functions as an opsonin [89], the increased C3 lev-
els together with the reduced Aβ deposition in the APP/
TGF-β1 mice suggested a neuroprotective role for comple-
ment in this model. To investigate this possibility, the APP
mice were crossed with mice expressing soluble comple-
ment receptor-related protein y (sCrry), a rodent-specific
inhibitor of early complement activation [90]. APP/sCrry
mice had a 2- to 3- fold increase in Aβ deposition in the
neocortex and hippocampus at 10–12 months of age,
together with a 50% loss of pyramidal neurons in hippoc-
ampal region CA3. The authors concluded that comple-
ment activation may protect against Aβ-induced toxicity,
and may reduce the accumulation or promote the clear-
ance of amyloid and degenerating neurons [88]. Neuro-
protective functions (protection against excitotoxicity)
have been demonstrated in vitro for C3a [52], and the
increased neuronal loss in the APP/sCrry mouse may be
due to decreased production of C3a as well as the
opsonin, C3b. However, whether inhibition of comple-
ment activation in the AD brain would similarly result in
increased neuropathology is unclear, because comple-
ment activation in AD is likely to be more extensive than
in the APP mouse. Although no peer-reviewed articles
have appeared in which the extent of complement activa-
tion in the APP mouse has been examined, two abstracts
have dealt with this issue. Yu et al. [91] reported C3, C5,
and C6 immunoreactivity to thioflavin-S-reactive plaques,
whereas McGeer et al. [92] found only weak complement
staining of plaques and slight upregulation of comple-
ment proteins. Significantly, neither study reported detec-
tion of the MAC. At least two factors, in addition to the
lack of NFTs, mitigate against complement activation in
the APP mouse being equivalent to that in AD: (a) the
mouse complement system is functionally deficient, as
mouse C4 lacks C5 convertase activity [93] and many
mouse strains have low complement levels relative to
other mammals [94], and (b) mouse C1q binds less effi-
ciently to human Aβ than does human C1q, resulting in
less activation of mouse complement than of human
complement in the presence of human Aβ [95].
PS/APP mouse
In addition to APP, mutations in the gene encoding for
presenilin-1 (PS-1) have also been associated with famil-
ial AD [96]. The PS/APP mouse carries both of these trans-
genes and has been extensively used as a model for
studying processes relating to the formation of SPs. Aβ
deposition occurs more rapidly in these mice than in the
single transgenic APP mouse [97]. In neither model does
NFT formation occur. Aβ deposition in PS/APP mice is
initially detected at 3 months of age, and increases with
age; total Aβ burden peaks at one year of age, although the
percentage of Aβ that is fibrillar (thioflavin-S reactive)
increases up to 2 years of age. Matsuoka et al. [98]
described the CNS inflammatory response to Aβ in these
animals. Activated astrocytes and microglia increased in
parallel with total Aβ and were closely associated with
both diffuse and fibrillar plaques. C1q immunoreactivity
was detected at both 7 and 12 months of age, co-localiz-
ing with activated microglia and fibrillar Aβ. These find-
ings were similar to those in the AD brain in that
complement activation was associated with SP formation.
The extent of complement activation was not addressed in
this study.
APP (Tg2576)/C1q-deficient mouse
Fonseca et al. [99] investigated the role of C1q in AD by
crossing Tg2576 (APP) mice [100] and APP/PS1 mice
with C1q knockout mice [101]. C1q immunoreactivity
was associated with plaque formation in the APP Tg2576
animals, as previously reported by Matsuoka et al. [98]. In
both the Tg2576/C1q- and APP/PS1/C1q- animals, lack of
C1q did not alter either plaque density or the time course
of plaque deposition. Neuronal cell numbers (NeuN+
cells), assessed only in the Tg2576 (APP) mouse, were not
changed by the absence of C1q; however, immunoreactiv-
ity to MAP-2 (a marker for neuronal dendrites and cell
bodies) and synaptophysin (a marker for presynaptic ter-
minals) in the hippocampus (region CA3) was increased
2-fold in the APP/C1q- animals, compared with APP mice.
Microglial and astrocytic activation was significantly
reduced in the APP/C1q- animals. These results were inter-
preted to suggest that in these animal models of AD, (1)
early complement activation (as indicated by C1q deposi-
tion) in response to fibrillar Aβ deposition might be
responsible for the chemotactic attraction of activated
glial cells, and (2) the activated microglia, while unable to
clear fibrillar Aβ, may have contributed to the loss of neu-
ronal integrity indicated by reduced MAP-2 and synapto-
physin staining in the APP mice. By recruiting activated
microglia, complement activation could potentially con-Journal of Neuroinflammation 2004, 1:18 http://www.jneuroinflammation.com/content/1/1/18
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tribute to neuronal injury even if full activation (MAC for-
mation) does not occur.
Postischemic hyperthermic rat model
Coimbra and colleagues [102] described progressive neu-
ronal loss in the hippocampus and cerebral cortex in rats
subjected to common carotid artery occlusion to produce
transient forebrain ischemia, as an animal model for
stroke. The post-surgical hyperthermia which occurs
spontaneously in these animals was suggested to promote
the infiltration of microglia, whose secretory products
increased the subsequent neuronal loss. A later study by
the same group [103] found that subjecting the rats to
post-surgical hyperthermia (38.5 – 40°C) increased
microglial and astrocytic infiltration and accompanying
neuronal loss, and resulted in the formation of AD-type
pathology. Aβ-reactive diffuse plaques were detected in
the cerebral cortex at 2 months post-surgery, with more
compact plaques in the hippocampus and cortex by 6
months. Increased ubiquitin and phosphorylated tau
immunoreactivity was observed at both time points,
together with staining for C5b-9 in the somatosensory
cortex. The MAC immunoreactivity co-localized with acid
fuchsin staining, a marker for neuronal death [104]. Other
complement proteins were not evaluated in these studies.
This is apparently the only animal model of AD in which
full complement activation has been reported. It is note-
worthy that while both SPs and neurofibrillary pathology
were present in these animals, the MAC apparently did
not co-localize with these structures, unlike in AD.
Acute lesioning
Alterations in native complement mRNA and protein lev-
els have been evaluated in the rat hippocampus following
experimental induction of acute neuronal injury. These
surgical and pharmacological procedures result in neuro-
nal loss in the entorhinal cortex, and deafferentation of
hippocampal neurons, similar to that which occurs in AD
[105]. Selective damage to the rat hippocampus has been
induced by surgical transection of the perforant pathway,
which runs between the entorhinal cortex and the molec-
ular layer of the dentate gyrus [106,107], systemic admin-
istration of the excitotoxin kainic acid [108,109], or
injection of the neurotoxin colchicine into the dorsal hip-
pocampus [109]. Surgical transection of the perforant
pathway increased C1qB mRNA in the entorhinal cortex
and hippocampus [106] and C9 immunoreactivity in the
hippocampus [107]. Injection of kainic acid similarly
increased C1qB and C4 mRNA expression and C1q
immunoreactivity in the hippocampus [108,109]. Colch-
icine infusion into the dorsal hippocampus, which selec-
tively damages granule cells of the dentate gyrus,
produced elevated mRNA expression of hippocampal
C1qB and C4 [109]. Though the acute neuronal damage
in these studies differs from the chronic, progressive neu-
rodegenerative process that occurs in AD, these results
demonstrated that the neuronal response to injury
includes upregulation of native complement protein syn-
thesis. The significance of this upregulation, i.e. whether it
promotes neuroprotection or neurotoxicity, was not
addressed.
Infusion of Aβ and C1q into rats
Frautschy et al. [56] examined the effects of infusion of
human C1q and oral administration of rosmarinic acid
on glial cell proliferation (microgliosis and astrocytosis),
plaque load, and memory (Morris water maze) in Aβ-
infused rats. Rosmarinic acid inhibits both the classical
and the alternative complement cascades, by covalent
binding to newly formed C3b [110]; it also possesses anti-
inflammatory [111,112], anti-oxidative [113], and anti-
amyloidogenic properties [114]. Gliosis was greater with
C1q and Aβ infusion than with Aβ alone. Plaque density
was decreased by C1q infusion (note: this result differs
from the in vitro study of Webster et al. [57], in which C1q
was found to inhibit microglial phagocytosis of Aβ, and
also from the recent study of Fonseca et al. [99] in which
C1q deficiency had no effect on plaque density in APP
mice), but, curiously, performance in the water maze
worsened. Treatment with rosmarinic acid had the oppo-
site effect; though plaque load increased, memory was
improved. These findings were interpreted as suggesting
that C1q and/or complement activation may, by promot-
ing microglial activation, worsen memory independent of
the clearance of Aβ.
Additional animal models for studying AD-related 
complement activation
TAPP and 3xTg-AD mice
Mutations in the gene encoding for human tau protein
have been linked to the development of frontotemporal
dementia with parkinsonism [115]. By combining this
mutation with the human APP and PS1 mutations associ-
ated with familial AD, animal models of AD have been
produced in which NFTs as well as SPs are formed. Lewis
et al. [116] crossed human APPswe mice (Tg2576) with
mice expressing the transgene for a human tau mutation
(JNPL3 mice) to generate a double mutant tau/APP
mouse (the "TAPP mouse"). These mice develop SPs sim-
ilar to APP mice (high numbers of plaques are present in
older [8.5–15 months of age] mice, in the olfactory cortex,
cingulate gyrus, amygdala, entorhinal cortex, and
hippocampus), and older TAPP mice have NFTs, in asso-
ciation with increased astrocyte proliferation, in limbic
areas. The plaques contain both Aβ40 and Aβ42. Oddo et
al. [117] injected the human transgenes for APP and
mutated tau into embryos of PS1 "knock-in" mice, gener-
ating the "3xTg-AD" mouse which develops both SPs and
NFTs in an age-related, region-specific manner. Aβ depo-
sition in these animals precedes NFT formation, withJournal of Neuroinflammation 2004, 1:18 http://www.jneuroinflammation.com/content/1/1/18
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extracellular Aβ (primarily Aβ42) detected in the frontal
cortex by 6 months of age, and in other cortical regions
and hippocampus by 12 months. Many of the extracellu-
lar Aβ deposits are thioflavin-S-positive and are associated
with reactive astrocytes. Phosphorylated tau initially
appears in the hippocampus and subsequently in cortical
regions; it is detected within neurons by 12–15 months
and within dystrophic neurites at 18 months. Though Aβ
immunoreactivity precedes that of tau, these proteins co-
localize to the same neurons. The presence of NFTs as well
as SPs suggests that the 3xTg-AD and TAPP models may be
more relevant than APP or APP/PS-1 mice for studying the
significance of complement activation in the develop-
ment of AD-type pathology. Potential drawbacks for using
these models for complement-related studies include, as
discussed earlier, functional deficiencies in activation of
mouse complement [93], decreased complement levels in
common laboratory mouse strains [94], and the
decreased efficiency of binding of mouse C1q by the
human Aβ within the SPs in these animals [95]. It is not
known whether a similar decrease in the efficiency of acti-
vation of mouse complement occurs when mouse C1q
binds to human, rather than murine, tau protein.
AD11 (anti-NGF) mouse
Ruberti et al. [118] developed a mouse transgenic model,
the AD11 mouse, in which neutralizing antibody to nerve
growth factor (NGF) is secreted by neurons and glial cells.
NGF exerts trophic effects on basal forebrain cholinergic
neurons and is widely distributed in these neurons [119];
the local secretion of anti-NGF antibody in these mice
results in marked loss of basal forebrain cholinergic neu-
rons. Aβ-containing plaques, tau hyperphosphorylation,
and NFTs are present at 15–18 months of age. CNS pro-
duction of anti-NGF antibody increases with age in these
animals, therefore pathology develops only in adult mice.
Extracellular deposition of APP is widespread in the brain,
including the cortex and hippocampus. Phosphorylated
tau immunoreactivity is present in neurons and glia in the
cortex and hippocampus, and intracellular NFTs, extracel-
lular neurofibrillary deposits, neuropil threads, and dys-
trophic neurites are observed in the cortex. Behavioral
abnormalities, including impaired object recognition and
spatial learning, are associated with this neuropathology
[120]. The Aβ-containing plaques in the AD11 mouse are
of murine, rather than human, origin, allowing the prob-
lem of the poor efficiency of activation of mouse comple-
ment by human Aβ [95] to be overcome. However, it is
unclear whether plaques in these animals contain Aβ in
the β-pleated sheet conformation, which is thought to be
the most effective conformation for activating comple-
ment [71]. The distribution of SPs and NFTs in this model
is less similar to AD than for 3xTg-AD and TAPP mice,
because in addition to the cortex and hippocampus, large
numbers of APP-reactive structures are present in the
neostriatum (where, in AD, plaques are primarily diffuse
[121]), and in other areas of the brain. Despite these con-
cerns, the AD11 mouse is attractive as a potential model
for studying the significance of AD-related complement
activation.
Chlamydia pneumoniae-infected mouse
C. pneumoniae is an intracellular, gram-negative or gram-
variable bacterium long identified as a respiratory patho-
gen. It has more recently been demonstrated to be a caus-
ative agent in reactive arthritis [122] and to be associated
with autoimmune disorders including multiple sclerosis
[123] and atherosclerosis [124]. Some laboratories have
also reported an association of this agent with AD [125-
127], although this has not been confirmed by others
[128-131]. A recent study by Little et al. [132] examined
the hypothesis that experimental C. pneumoniae infection
in BALB/c mice could produce AD-like pathology. Intra-
nasal inoculation with C. pneumoniae resulted in deposi-
tion of Aβ1–42 in the hippocampus, amygdala, entorhinal
cortex, perirhinal cortex, and thalamus by 3 months post-
inoculation. The majority of these Aβ deposits appeared
similar to diffuse plaques, though a small number of them
were thioflavin-S-reactive. NFTs were not detected. The
authors suggested that soluble factors such as lipopolysac-
charides, which are present in the cell wall of all Chlamy-
diae [133], may have been responsible for the altered
amyloid processing which resulted in Aβ deposition.
Because the Aβ within the SPs in these animals is of
endogenous origin, and because other chlamydial species
have been shown to activate complement [134,135], the
C. pneumoniae-infected mouse may offer a novel infec-
tious model for studying the relationship of complement
activation to the development of Aβ-containing plaques.
Aged dogs
Old dogs, in particular the beagle, have been extensively
investigated as a model for CNS Aβ deposition and asso-
ciated age-related cognitive dysfunction. Aβ deposits are
detectable in the brains of most older dogs [136]. The
regional distribution of Aβ in the dog brain resembles that
in humans, found initially in the prefrontal cortex, subse-
quently in entorhinal and parietal cortices, and lastly in
occipital cortex [137]. Aβ42 is the predominant type of Aβ
deposited in plaques [138]. Canine plaques are nonfibril-
lar and do not contain neuritic elements; thus, they resem-
ble diffuse Aβ deposits in the human brain, but not the
mature plaques predominating in AD. The neuropatho-
logical findings in old dogs also differ from AD in that
activated glial cells are rarely associated with Aβ deposits,
and NFTs are not detected [136,139]. Age-related cogni-
tive impairment, termed "canine cognitive dysfunction
syndrome," occurs in some older dogs and correlates with
Aβ deposition in the hippocampus and frontal cortex
[140,141]. The endogenous nature of the deposited Aβ inJournal of Neuroinflammation 2004, 1:18 http://www.jneuroinflammation.com/content/1/1/18
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old dog brain, and similarities between canine and
human Aβ in their patterns of regional deposition, suggest
that this model may be useful for studying the relation-
ship between complement activation and plaque
formation.
Non-human primates
Age-related formation of SPs has been reported in a vari-
ety of non-human primates including the cynomolgus
monkey [142], rhesus monkey [143], chimpanzee [144],
and marmoset [145]. Aβ within these plaques is predom-
inantly Aβ40 [146]. NFTs apparently do not form in the
brains of most aged primates, with a few exceptions. The
brain of the aged baboon contains phosphorylated tau
protein [147,148], and an age-related accumulation of tau
also occurs in the neocortex of the mouse lemur [149-
151]. In this latter species, Aβ deposition occurs in the cer-
ebral cortex and amygdala but is not age-dependent [151].
The mouse lemur appears to be the most promising pri-
mate species to date for studying the significance of AD-
related complement activation because of the presence of
NFTs as well as plaques.
Other animal species
Scattered reports of AD-type pathology in other species
have also appeared. Adding trace amounts of copper to
the water supply of cholesterol-fed rabbits results in Aβ
deposition within SP-like structures in the hippocampus
and temporal cortex, with associated learning deficits
[152]. The neuropathology in the aged cat is similar to
that in the old dog in that Aβ is deposited only as diffuse,
Aβ42-containing plaques, and NFTs are not detected [138].
A report of AD-type pathology in an aged wolverine [153]
described neuritic as well as diffuse plaques in the cortex
and hippocampus, and intracellular NFTs containing
phosphorylated tau protein in cortical and hippocampal
neurons. Finally, the aged polar bear brain also contains
both diffuse plaques and NFTs [154]. While the neu-
ropathological findings in the aged wolverine and polar
bear resemble AD more closely than in most species
examined to date, their inaccessibility to laboratory
researchers limits the usefulness of these species for stud-
ies of AD-related complement activation.
Conclusions
1. Complement activation has been extensively studied in
the AD brain. There is convincing evidence for activation
of both the classical and alternative pathways, resulting in
full activation as indicated by the presence of the MAC.
Both aggregated Aβ (in SPs) and phosphorylated tau (in
NFTs) are likely to be responsible for this activation.
2. Because complement activation generates both both
neuroprotective and neurotoxic effects, the significance of
increased complement activation in the development and
progression of AD is unclear.
3. An optimal animal model for studying the significance
of complement activation in the development of AD-type
pathology would have complete activation of this process,
with co-localization of complement activation proteins
with SPs and with NFTs (if present). Other desirable fea-
tures include early complement activation prior to the
development of extensive neuropathology, increased CNS
production of native complement proteins, and both clas-
sical and alternative pathway activation.
4. Surprisingly little is known about the extent of comple-
ment activation in animal models of AD. The pos-
tischemic hyperthermic rat [103] is the only animal
model of AD in which full complement activation has
been reported. The few studies with APP-transgenic mice
have yielded conflicting results, with one investigation
suggesting a neuroprotective role for complement activa-
tion [88], while another found that early complement
activation (as indicated by C1q deposition) was associ-
ated with a loss of neuronal integrity [99]. Transgenic
mouse models may be problematic for studies of AD-
related complement activation because of inherent defi-
ciencies in mouse complement activation and inefficient
activation of mouse complement by the human Aβ
present in the SPs in these animals. Other animal models
in which SPs (and NFTs, if present) are of endogenous,
rather than human, origin offer alternatives to transgenic
mice for studying this issue.
5. The extent of complement activation and its association
with neuropathology must be determined in animal mod-
els of AD to clarify the relevance of these models for inves-
tigating the significance of complement activation in the
development of AD-type pathology.
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